Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder

  • Original Paper
  • Published:
Urological Research Aims and scope Submit manuscript

Abstract

Several urinary markers for transitional cell carcinoma have been investigated, including urine cytology, bladder tumor antigen, autocrine motility factor receptor and fibrin degradation products. Unfortunately, they have poor overall sensitivity. The United States Food and Drug Administration have recently approved nuclear matrix protein (NMP 22) for the detection of occult or rapidly recurring disease after transurethral resection of bladder tumor. The objective of the current study was to assess the sensitivity of NMP 22 for the detection of bladder carcinoma, as well as to correlate the NMP 22 values with multiplicity of tumor, tumor size, configuration, stage and grade respectively. A total of 78 patients (38 with bladder cancer) provided a urine sample which was divided into appropriate aliquots for each of urine cytology and NMP 22. Comparative results demonstrate a clear superiority of NMP 22 in bladder cancer detection (52.6% vs 31.6% sensitivity), while specificity was in favor of urine cytology (100% vs 82.5%). For superficial tumors, sensitivity was 78.5% for NMP 22 and 41.6% for cytology and for invasive cancers, sensitivity was 90% for NMP 22 and 60% for cytology. Urinary NMP 22 levels were significantly correlated with tumor grade and were significantly higher in large tumors than small tumors. NMP 22 test results showed sufficient sensitivity in comparison with urine cytology for the detection of transitional cell carcinoma. However, we do not think that it is a useful tool as a substitute for endoscopic examination for the detection and surveillance in bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee R, Droller MJ (2000) The natural history of bladder cancer. Urol Clin North Am 27:1–12

    Article  CAS  PubMed  Google Scholar 

  2. Abel PD (1988) Prognostic indices in transitional cell carcinoma of the bladder. Brit J Urol 62:103

    CAS  PubMed  Google Scholar 

  3. Brown FM (2000) Urine cytology: is it still the gold standard for screening? Urol Clin North Am 27:25–36

    CAS  PubMed  Google Scholar 

  4. Korman HJ, Peabody JO, Cerny JC, Farh RN, Yao J, Raz A (1996) Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J Urol 155:347

    Article  CAS  PubMed  Google Scholar 

  5. Schmetter BS, Habicht KK, Lamm DL, Morales A, Grossman HB, Bander N et al. (1996) Results of a multicenter trial evaluation of Aura-Tek FDP: an aid in the management of bladder cancer patients. J Urol 155:492A

    Google Scholar 

  6. Sarosdy MF, De Vere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF et al. (1995) Results of a multicenter trial using BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154:379

    CAS  PubMed  Google Scholar 

  7. Keesee SK, Meneghini MD, Szaro RP, Wu YJ (1994) Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci U S A 91:1913

    CAS  PubMed  Google Scholar 

  8. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S et al. (1993) Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53:3394

    PubMed  Google Scholar 

  9. Bidwell JP, Fey EG, Van Wijnen AJ, Penman S, Stein JL, Lian JB et al. (1994) Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 54:28

    CAS  PubMed  Google Scholar 

  10. Grocela JA, McDougal WS (2000) Utility of nuclear matrix protein (NMP 22) in the detection of recurrent bladder cancer. Urol Clin North Am 27:47–50

    CAS  PubMed  Google Scholar 

  11. Boman H, Hedelin H, Holmang S (2002) Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167:80–83

    Article  PubMed  Google Scholar 

  12. Hermonek P, Sobin LH (1987) UICC-International Union against Cancer. TNM classification of malignant tumors, 4th edn. Springer-Verlag, Heidelberg

  13. Mostofi FK, Sobin LH, Torloni H (1973) Histologic typing of urinary bladder tumors (International Histologic Classification of Tumors No.10). World Health Organization, Geneva

  14. Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101:519–520

    Google Scholar 

  15. Badalament RA, Hemansen DK, Kimmel M, Gay H, Herr HW, Fair WR et al. (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer 60:1423

    CAS  PubMed  Google Scholar 

  16. Carpinito GA, Stadler WM, Brigmann JV, Chodak GW, Church PA, Lamm DL et al. (1996) Urinary nuclear matrix proteins as a marker for transitional cell carcinoma of the urinary tract. J Urol 156:1280

    Article  CAS  PubMed  Google Scholar 

  17. Miyanaga N, Akaza D, Ishikawa T, Ohtani M, Naguchi R, Kawai K et al. (1997) Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 31:163–168

    CAS  PubMed  Google Scholar 

  18. Sözen S, Biri H, Sınık Z, Küpeli B, Alkibay T, Bozkırlı İ (1999) Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 36:225–229

    Article  PubMed  Google Scholar 

  19. Soloway MS, Brigmann JV, Carpinito GA, Chodak GW, Church PA, Lamm DL et al. (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156:363–367

    Article  CAS  PubMed  Google Scholar 

  20. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al. (1998) Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159:394-398

    CAS  PubMed  Google Scholar 

  21. Wiener HG, Mian C, Haitel A et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 159:1876-1880

  22. Ramakumar S, Bhuiyan J, Besse JA et al. (1999) Comparison of screening methods in the detection of bladder cancer. J Urol 161:388-394

    Article  CAS  PubMed  Google Scholar 

  23. Del Nero A, Esposito N, Currò A et al. (1999) Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 35:93-97

    Article  PubMed  Google Scholar 

  24. Sanchez-Carbayo M, Herrero E, Megias J et al. (1999) Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. Br J Urol 84:706-713

    Article  CAS  Google Scholar 

  25. Casella R, Huber P, Blöchlinger A et al. (2000) Urinary level of NMP 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol 164:1926–1928

    Article  CAS  PubMed  Google Scholar 

  26. Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen RW (1983) Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14:140

    CAS  PubMed  Google Scholar 

  27. Renshaw AA, Nappi D, Weinberg DS (1996) Cytology of grade 2 papillary transitional cell carcinoma: a comparison of cytologic, architectural and morphometric criteria in cystopically obtained urine. Acta Cytol 40:676–682

    CAS  PubMed  Google Scholar 

  28. Wiener HG, Vooijs GP, Van’t Hof-Grootenboer B (1993) Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 37:163

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Celal Bayar University, School of Medicine, Department of Urology/Manisa, 45010 Turkey

    Murat Lekili, Ercüment Şener, Gökhan Temeltaş, Talha Müezzinoğlu & Coşkun Büyüksu

  2. Celal Bayar University, School of Medicine, Department of Pathology/Manisa, 45010 Turkey

    Mehmet Akif Demir

Authors
  1. Murat Lekili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ercüment Şener
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Akif Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gökhan Temeltaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Talha Müezzinoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Coşkun Büyüksu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murat Lekili.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lekili, M., Şener, E., Demir, M.A. et al. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res 32, 124–128 (2004). https://doi.org/10.1007/s00240-003-0394-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00240-003-0394-2

Keywords

Search

Navigation